finance.yahoo.com ·
Palisade Bio Pali Reports Q1
Topic context
This topic has been covered 373758 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedPalisade Bio is a pre-revenue biotech advancing PALI-2108 for IBD. The Q1 2026 earnings show increased R&D spend, but no commercial product or revenue yet. The commercial mechanism is weak: no approved drug, no pricing, no supply chain impact. The only signal is the company's progress toward Phase 2 trials, which may affect future licensing or partnership value but has no current market impact.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Palisade Bio Q1 2026 R&D costs rose to $6.4M from $1.0M in Q1 2025.
- Lead candidate PALI-2108 for IBD achieved positive Phase 1a/b results in ulcerative colitis and promising Phase 1b data in Crohn’s disease.
- IND for Phase 2 ulcerative colitis trial expected Q2 2026; trial initiation Q3 2026; primary efficacy readout H2 2027.
- IND for Phase 2 Crohn’s disease trial expected H2 2026; trial initiation Q1 2027.
Related stories
finance.yahoo.com
Eurodry Edry Q1 2026 Earnings
zerohedge.com
Europe Primed Lower Open Amid Lack Progress Usiran Hefty Speaker Slate Nvidia Earnings Due
fool.com
Keysight Keys Q2 2026 Earnings Transcript
fool.com
Xcel Brands Xelb Q4 2025 Earnings Transcript
livemint.com